CRBP

Corbus Pharmaceuticals Holdings (CRBP)

About Corbus Pharmaceuticals Holdings (CRBP)

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Details

Daily high
$8.78
Daily low
$8.15
Price at open
$8.70
52 Week High
$61.90
52 Week Low
$8.01
Market cap
100.0M
Dividend yield
0.00%
Volume
250,937
Avg. volume
303,455
P/E ratio
-1.75

Corbus Pharmaceuticals Holdings News

Details

Daily high
$8.78
Daily low
$8.15
Price at open
$8.70
52 Week High
$61.90
52 Week Low
$8.01
Market cap
100.0M
Dividend yield
0.00%
Volume
250,937
Avg. volume
303,455
P/E ratio
-1.75